The U.S. Centers for Medicare & Medicaid Services has announced the 15 new drugs that will be targeted for Medicare price negotiations in 2028, including Pfizer's arthritis treatment Xeljanz, Eli Lilly's diabetes drug Trulicity, and AbbVie's cosmetic treatment Botox. This marks the third round of drugs subject to the annual price negotiations established under President Joe Biden's Inflation Reduction Act (IRA) of 2022. Notably, the list includes the first products reimbursed under Medicare Part B, a significant development in healthcare policy. The U.S. Medicare health plan estimates that the newly negotiated prices for these 15 drugs will result in substantial savings, reducing prescription costs by 36% compared to recent annual spending, which equates to approximately $8.5 billion in net covered prescription costs. This initiative is expected to have a significant impact on the pharmaceutical industry and healthcare costs, sparking discussions on the future of drug pricing and accessibility.
